Investing.com -- Royalty Pharma plc (NASDAQ:RPRX) stock rose 2.4% in Tuesday’s premarket trading after the company announced it has acquired royalty rights to two promising cancer therapies from an undisclosed third party.
The company is purchasing a pre-existing low-single digit royalty interest in Nuvalent’s neladalkib and zidesamtinib for up to $315 million. Both drugs are next-generation tyrosine kinase inhibitors (TKIs) designed to treat specific mutations of non-small cell lung cancer (NSCLC).
Neladalkib, which targets ALK mutation-positive NSCLC, showed positive pivotal results in TKI pre-treated patients in November 2025, demonstrating durable activity and a generally well-tolerated safety profile. The drug is also being evaluated in an ongoing Phase 3 study for TKI-naïve patients.
Zidesamtinib, developed for ROS1 mutation-positive NSCLC, is currently under review by the U.S. Food and Drug Administration with an action date of September 18, 2026, for TKI pre-treated patients. It is also being assessed in an ongoing Phase 1/2 study in TKI-naïve patients.
According to existing analyst consensus, neladalkib sales are projected to reach approximately $3.5 billion by 2035, while zidesamtinib sales are expected to hit around $1.9 billion in the same timeframe.
The royalty rights Royalty Pharma has acquired are expected to extend through approximately 2041 to 2042 for both therapies, providing the company with a long-term revenue stream from these potential cancer treatments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
